secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2023-12-04T23:59:59+00:00
Accession:  0000950170-23-067774
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics updates on CAR T pipeline; shifts focus to CTX112/CTX131, CTX110 Part B shows 23% 6-month CR
--------------------------------------------------------------------------------

- Next-generation candidates CTX112 (CD19) and CTX131 (CD70) incorporate knock-out of Regnase-1 and TGFBR2 to enhance potency.
- Emerging data show CTX112 and CTX131 achieve significantly higher CAR T expansion and functional persistence in patients vs. first-gen.
- CTX110 Phase 1/2 Part B reported increased 6-month complete response rate of 23%, up from 19% in Part A.
- Company will transition CTX110 and CTX130 patients to long-term follow-up; CTX112 and CTX131 trials ongoing.
- Internal GMP facility manufacturing CTX112 and CTX131 for clinical trials; manufacturing robustness improved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023067774/0000950170-23-067774-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023067774/crsp-20231204.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-067774

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer